JPWO2022043895A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022043895A5 JPWO2022043895A5 JP2023513309A JP2023513309A JPWO2022043895A5 JP WO2022043895 A5 JPWO2022043895 A5 JP WO2022043895A5 JP 2023513309 A JP2023513309 A JP 2023513309A JP 2023513309 A JP2023513309 A JP 2023513309A JP WO2022043895 A5 JPWO2022043895 A5 JP WO2022043895A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- egfr
- pharmaceutical composition
- seq
- met
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069748P | 2020-08-25 | 2020-08-25 | |
| US63/069,748 | 2020-08-25 | ||
| PCT/IB2021/057794 WO2022043895A2 (en) | 2020-08-25 | 2021-08-25 | Treatment of non-small lung cancer with egfr mutations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023539589A JP2023539589A (ja) | 2023-09-15 |
| JP2023539589A5 JP2023539589A5 (https=) | 2024-09-02 |
| JPWO2022043895A5 true JPWO2022043895A5 (https=) | 2024-09-02 |
Family
ID=80352814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513309A Pending JP2023539589A (ja) | 2020-08-25 | 2021-08-25 | Ｅｇｆｒ変異を有する非小細胞肺がんの治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12528869B2 (https=) |
| EP (1) | EP4204455A4 (https=) |
| JP (1) | JP2023539589A (https=) |
| KR (1) | KR20230053686A (https=) |
| CN (1) | CN116194141A (https=) |
| AU (1) | AU2021330539A1 (https=) |
| CA (1) | CA3192922A1 (https=) |
| IL (1) | IL300854A (https=) |
| JO (1) | JOP20230039A1 (https=) |
| MX (1) | MX2023002362A (https=) |
| WO (1) | WO2022043895A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230174677A1 (en) * | 2021-11-16 | 2023-06-08 | Janssen Biotech, Inc. | Use of Approved Bispecific EGFR and Met Specific Antibody Drug Product to Treat Non-Small Cell Lung Cancer (NSCLCL) |
| US20240317866A1 (en) * | 2022-06-30 | 2024-09-26 | Janssen Biotech, Inc. | Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer |
| WO2024108193A2 (en) * | 2022-11-18 | 2024-05-23 | Epibiologics, Inc. | Degradation of cmet using a bispecific binding agent |
| CN116284335A (zh) * | 2023-03-17 | 2023-06-23 | 云南中医药大学 | Egfr基因突变体的检测方法及应用 |
| WO2025158277A1 (en) * | 2024-01-22 | 2025-07-31 | Janssen Biotech, Inc. | Use of amivantamab to treat head and neck cancer |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| EP1766068A4 (en) | 2004-06-04 | 2010-03-03 | Genentech Inc | EGFR Mutations |
| EP1789446A2 (en) | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| EP3511342B1 (en) | 2010-03-10 | 2024-01-17 | Genmab A/S | Monoclonal antibodies against c-met |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| WO2012142535A2 (en) | 2011-04-15 | 2012-10-18 | Esco Corporation | Replaceable wear parts for an earth-working roll |
| CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| US20170275367A1 (en) | 2012-11-21 | 2017-09-28 | Janssen Biotech, Inc. | Bispecific EGFR/C-Met Antibodies |
| CN113201073A (zh) * | 2012-11-21 | 2021-08-03 | 詹森生物科技公司 | 双特异性EGFR/c-Met抗体 |
| EP3029067A1 (en) | 2014-12-01 | 2016-06-08 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific T cell-activation |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| MA46852A (fr) | 2016-11-17 | 2019-09-25 | Univ Texas | Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20 |
| WO2020102647A1 (en) | 2018-11-15 | 2020-05-22 | Invenra Inc. | Multivalent receptor-clustering agonist antibody constructs and antigen binding proteins |
| SG11202108311RA (en) | 2019-02-26 | 2021-09-29 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| WO2020230091A1 (en) | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
| IL305700A (en) | 2021-03-09 | 2023-11-01 | Janssen Biotech Inc | Treatment of cancers lacking EFGR-activating mutations |
-
2021
- 2021-08-25 IL IL300854A patent/IL300854A/en unknown
- 2021-08-25 WO PCT/IB2021/057794 patent/WO2022043895A2/en not_active Ceased
- 2021-08-25 MX MX2023002362A patent/MX2023002362A/es unknown
- 2021-08-25 US US17/411,158 patent/US12528869B2/en active Active
- 2021-08-25 JP JP2023513309A patent/JP2023539589A/ja active Pending
- 2021-08-25 KR KR1020237009896A patent/KR20230053686A/ko active Pending
- 2021-08-25 CN CN202180052496.5A patent/CN116194141A/zh active Pending
- 2021-08-25 AU AU2021330539A patent/AU2021330539A1/en active Pending
- 2021-08-25 CA CA3192922A patent/CA3192922A1/en active Pending
- 2021-08-25 EP EP21860686.1A patent/EP4204455A4/en active Pending
-
2023
- 2023-02-23 JO JOJO/P/2023/0039A patent/JOP20230039A1/ar unknown
-
2025
- 2025-11-14 US US19/389,439 patent/US20260070993A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7608164B2 (ja) | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ | |
| JP2024153659A5 (https=) | ||
| EP3903828A1 (en) | Combination of antibody-drug conjugate and kinase inhibitor | |
| JP2021059564A (ja) | 癌治療のための併用療法 | |
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| CN101998851A (zh) | 吡铂和西妥昔单抗治疗结直肠癌的用途 | |
| JP2026021442A (ja) | 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療 | |
| EP4464337A1 (en) | Combined use of anti-trop-2 antibody-drug conjugate and other therapeutic agents | |
| EP3463453A1 (en) | Combination of pembrolizumab and abemaciclib for the treatment of cancer | |
| CN114340679A (zh) | 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物 | |
| JP2022533211A (ja) | 小細胞肺がんの併用療法用キノリン誘導体 | |
| JPWO2020174370A5 (https=) | ||
| CN104892763A (zh) | 抗体-药物偶联物Pertuzumab-MCC-DM1、其与Trastuzumab的组合物及其应用 | |
| JP2021073203A (ja) | Ｈｅｒ２陽性転移性乳癌の治療方法 | |
| US20080008704A1 (en) | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies | |
| JPWO2022043895A5 (https=) | ||
| WO2025103377A1 (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| JPWO2021161262A5 (https=) | ||
| EP3973963A1 (en) | Quinoline derivatives for treatment of head and neck cancer | |
| TW201922292A (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| JPWO2020230091A5 (https=) | ||
| JPWO2023105479A5 (https=) | ||
| CA3287886A1 (en) | Combination of anti-cdh6 antibody-drug conjugate and hif-2a inhibitor | |
| EP4691497A1 (en) | Combination of anti-cdh6 antibody-drug conjugate and hif-2alpha inhibitor | |
| JPWO2022189942A5 (https=) |